Answers are grounded in this paper and cite their sources.
A case report observes adult T-cell leukemia/lymphoma after liver transplantation, highlighting the need for careful monitoring.
• First reported case of ATLL occurring after liver transplantation for hepatocellular carcinoma. • Represents the first post-transplant ATLL case reported outside Japan. • ATLL developed 15 years after liver transplantation, the longest latency described to date. • Highlights the importance of surveillance for HTLV-1 carriers undergoing liver transplantation. Adult T-cell leukemia/lymphoma (ATLL) is a rare malignancy caused by human T-lymphotropic virus type 1 (HTLV-1). ATLL arising after liver transplantation is extremely uncommon, and all previously reported cases only involve recipients transplanted for acute liver failure. We report a 69-year-old man who developed acute-type ATLL 15 years after living-donor liver transplantation (LDLT) for hepatocellular carcinoma —representing the first such case in the literature and the longest latency described. He presented with gastrointestinal symptoms and leukocytosis with 32% atypical lymphocytes. Workup revealed HTLV-1 positivity, hypermetabolic lymphadenopathy, and bone marrow involvement. After the diagnosis of acute type ATLL, he received VCAP-AMP-VECP chemotherapy and intrathecal therapy, followed by interferon-α and allogeneic stem cell transplantation. Despite treatment, he developed severe complications and died 11 months after diagnosis. This case expands the clinical spectrum of post-transplant ATLL, demonstrating that disease may occur many years after transplantation and even in recipients transplanted for HCC rather than acute liver failure. We propose a risk-stratified surveillance strategy for HTLV-1 carriers after liver transplantation.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: